Abbvie INC Form 4 insider transactions

AbbVie Inc. director Susan E. Quaggin reported transactions involving stock equivalent units, reflecting compensation and dividend reinvestment.

AbbVie Inc. director Thomas J. Falk has reported transactions involving restricted stock units and common stock.

AbbVie Inc. director Frederick H. Waddell acquired restricted stock units under the company's incentive program.

AbbVie Inc. director Rebecca B. Roberts acquired 1,118 restricted stock units under the company's incentive program.

AbbVie Inc. director Edward J. Rapp has reported transactions involving restricted stock units and common stock, reflecting changes in beneficial ownership.

AbbVie Inc. director Susan E. Quaggin reported the acquisition of 1,118 restricted stock units under the company's incentive stock program.

AbbVie Inc. director Melody B. Meyer acquired 1,118 shares of common stock through restricted stock units awarded under the company's incentive program.

AbbVie Inc. director Brett J. Hart reported the acquisition of 1,118 restricted stock units under the company's incentive program.

AbbVie Inc. director Thomas C. Freyman reported transactions involving restricted stock units and common stock.

AbbVie Inc. director Jennifer L. Davis acquired 1,118 restricted stock units under the company's incentive program.

AbbVie Inc. director William H.L. Burnside acquired restricted stock units under the company's incentive program.

AbbVie Inc. director Roxanne S. Austin reported the acquisition of 1,118 restricted stock units under the company's incentive stock program.

AbbVie Inc. director Susan E. Quaggin reported transactions involving stock equivalent units, reflecting director fees and dividend reinvestment.

AbbVie Inc. director Edward J. Rapp has reported transactions related to stock equivalent units, reflecting his compensation and beneficial ownership.

AbbVie Inc. Director Robert J. Alpern filed a Form 4 detailing transactions related to stock equivalent units held in grantor trusts.

AbbVie's SVP, Controller, David Ryan Purdue, sold 5,230 shares of common stock for $233.56 per share in a pre-planned transaction.

AbbVie's EVP, Chief HR Officer, Demetris D. Crum, disposed of 1,594 shares of common stock to cover tax withholding obligations.

AbbVie's EVP of R&D and CSO, Roopal Thakkar, reported the disposition of 8,037 shares of common stock to cover tax liabilities.

AbbVie's Chairman and CEO, Robert A. Michael, reported the disposition of 36,523 common shares for tax withholding purposes at a price of $232.08 per share.

AbbVie's EVP, Chief Commercial Officer, Jeffrey Ryan Stewart, disposed of 23,812 shares of common stock to cover tax liabilities.

AbbVie's Executive Vice President, General Counsel, and Secretary, Perry C. Siatis, reported the sale of company common stock totaling 18,668 shares under a pre-arranged trading plan.

AbbVie's EVP and Chief Financial Officer, Scott T. Reents, disposed of 21,638 shares of common stock to cover tax liabilities related to equity compensation.

AbbVie's EVP and Chief Operations Officer, Azita Saleki-Gerhardt, reported a sale of 16,309 common shares to cover tax liabilities at a price of $232.08 per share.

AbbVie's SVP, Controller, David Ryan Purdue, disposed of 2,692 shares of common stock at $232.08 per share for tax liability on February 27, 2026.

AbbVie's EVP, Chief Business and Strategy Officer, Nicholas Donoghoe, disposed of 12,874 shares of common stock to cover tax withholding obligations.

AbbVie's EVP, GC and Secretary, Perry C. Siatis, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 plan.

AbbVie Director Robert J. Alpern reported the acquisition of 34 stock equivalent units on December 31, 2025, as part of director compensation.

AbbVie Inc. Director Susan E. Quaggin reported a planned acquisition of 68 stock equivalent units under a Rule 10b5-1 plan, increasing her beneficial ownership to 707 units.

AbbVie Director Edward J. Rapp acquired 147 stock equivalent units, increasing his beneficial ownership to 28,498 units, as part of director fee compensation.

AbbVie Director Susan E. Quaggin acquired 67 stock equivalent units, valued at $231.54 each, as part of her director compensation.